Movatterモバイル変換

[0]ホーム
URL:

SG10201901391RA - Induction of il-12 using immunotherapy - Google Patents

Induction of il-12 using immunotherapy

Info

Publication number
SG10201901391RA
SG10201901391RASG10201901391RASG10201901391RASG10201901391RASG 10201901391R ASG10201901391R ASG 10201901391RASG 10201901391R ASG10201901391R ASG 10201901391RASG 10201901391R ASG10201901391R ASG 10201901391RASG 10201901391R ASG10201901391R ASG 10201901391RA
Authority
SG
Singapore
Prior art keywords
patient
induction
immunotherapy
composition
skews
Prior art date
Application number
SG10201901391RA
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies LtdfiledCriticalImmunovative Therapies Ltd
Publication of SG10201901391RApublicationCriticalpatent/SG10201901391RA/en

Links

Classifications

Landscapes

Abstract

INDUCTION OF IL-12 USING IMMUNOTHERAPY The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Thl environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity. (FIGURE 1)
SG10201901391RA2011-05-032012-05-02Induction of il-12 using immunotherapySG10201901391RA (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201161482009P2011-05-032011-05-03
US201161528484P2011-08-292011-08-29
US201161564551P2011-11-292011-11-29
US201261582881P2012-01-042012-01-04

Publications (1)

Publication NumberPublication Date
SG10201901391RAtrue SG10201901391RA (en)2019-03-28

Family

ID=47108207

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201901391RASG10201901391RA (en)2011-05-032012-05-02Induction of il-12 using immunotherapy
SG2013081302ASG194753A1 (en)2011-05-032012-05-02Induction of il-12 using immunotherapy

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG2013081302ASG194753A1 (en)2011-05-032012-05-02Induction of il-12 using immunotherapy

Country Status (12)

CountryLink
US (4)US9233156B2 (en)
EP (1)EP2704732B1 (en)
JP (2)JP6393186B2 (en)
KR (1)KR102121492B1 (en)
CN (2)CN109876138A (en)
AU (3)AU2012250807A1 (en)
BR (1)BR112013028285A2 (en)
CA (1)CA2838046C (en)
IL (1)IL229177B (en)
PH (1)PH12013502252B1 (en)
SG (2)SG10201901391RA (en)
WO (1)WO2012151279A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SG10201901391RA (en)2011-05-032019-03-28Immunovative Therapies LtdInduction of il-12 using immunotherapy
MX390311B (en)2013-12-052025-03-20Rfemb Holdings Llc PRESENTATION OF ENHANCED CANCER ANTIGEN TO CELLS PRESENTING BY ELECTRICAL MEMBRANE BREAKDOWN BY RADIOFREQUENCY (RF-RMB) AS AN ADJUVANT MECHANISM FOR IMMUNOTHERAPY.
JP6202339B2 (en)*2013-12-192017-09-27国立研究開発法人国立精神・神経医療研究センター GM-CSF producing T cell regulator and Th1 / Th2 immune balance regulator
EP3250142A4 (en)2015-01-302018-11-21Rfemb Holdings LLCRadio-frequency electrical membrane breakdown for the treatment of tissues
US11612426B2 (en)*2016-01-152023-03-28Immunsys, Inc.Immunologic treatment of cancer
WO2019014511A2 (en)*2017-07-142019-01-17Minzhen XuMethod for inducing an m1 dominated immune response and pharmaceutical compositions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2439003A1 (en)1978-10-201980-05-16Anvar NEW OSTEOSYNTHESIS PARTS, THEIR PREPARATION AND THEIR APPLICATION
US5766920A (en)1982-08-111998-06-16Cellcor, Inc.Ex vivo activation of immune cells
WO1988000970A2 (en)1986-08-081988-02-11Regents Of The University Of MinnesotaMethod of culturing leukocytes
ZA888978B (en)1987-12-041990-07-25Du PontImmobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
US6352694B1 (en)1994-06-032002-03-05Genetics Institute, Inc.Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en)1988-11-232005-06-14Genetics Institute, Inc.Methods of treating HIV infected subjects
US6534055B1 (en)1988-11-232003-03-18Genetics Institute, Inc.Methods for selectively stimulating proliferation of T cells
US5126132A (en)1989-08-211992-06-30The United States Of America As Represented By The Department Of Health And Human ServicesTumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en)1989-10-031998-03-17Terman; David S.Method of cancer treatment
JPH0455577A (en)1990-06-221992-02-24Mitsubishi Electric CorpVibration controlling device of construction
WO1994012196A1 (en)1992-11-251994-06-09Tanox Biosystems, Inc.Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
AU7478394A (en)1993-08-061995-02-28Cytel CorporationMethods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en)1993-11-031994-02-27Yeda Res & DevBone marrow transplantation
US5827642A (en)1994-08-311998-10-27Fred Hutchinson Cancer Research CenterRapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6461867B1 (en)1995-03-082002-10-08The Scripps Research InstituteSynthetic antigen presenting matrix
DE19545257A1 (en)1995-11-241997-06-19Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
JPH09255577A (en)*1996-03-271997-09-30Dainippon Ink & Chem Inc Interryukin-12 inducer
CA2254975C (en)1996-05-232008-12-16The Scripps Research InstituteMhc class ii antigen-presenting systems and methods for activating cd4+ t cells
EP1018982B1 (en)1996-12-032005-03-09Osteobiologics, Inc.Biodegradable polymeric film
US6194207B1 (en)1997-01-312001-02-27Hemosol Inc.Methods for the selective expansion of lymphocytes by in vitro cultivation
ATE412383T1 (en)1997-05-302008-11-15Osteobiologics Inc FIBER REINFORCED POROUS BIODEGRADABLE IMPLANT DEVICE
JP2001522806A (en)1997-11-102001-11-20アーチ・デヴェロップメント・コーポレイション Methods for treating tumors and tumor cells using ex vivo activated T cells
JP2001054563A (en)1999-07-122001-02-27Isotis BvSuture
US6867041B2 (en)2000-02-242005-03-15Xcyte Therapies, Inc.Simultaneous stimulation and concentration of cells
US20030119185A1 (en)2000-02-242003-06-26Xcyte Therapies, Inc.Activation and expansion of cells
HK1047770A1 (en)2000-02-242003-03-07Xcyte Therapies, Inc.Simultaneous stimulation and concentration of cells
WO2001062092A1 (en)*2000-02-252001-08-30Thomas Jefferson UniversityFormulations and methods for using the same to elicit an immune response
US20020127208A1 (en)2000-08-312002-09-12Waller Edmund K.Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en)2001-06-282003-09-30Ethicon, Inc.Composite scaffold with post anchor for the repair and regeneration of tissue
US20030134415A1 (en)*2001-09-192003-07-17Gruenberg Micheal L.Th1 cell adoptive immunotherapy
AU2002342299A1 (en)2001-10-312003-05-12The Government Of The United States Of America, As Represented By The Secretary Of The Department OfGeneration of use of tc1 and tc2 cells
WO2003053216A2 (en)2001-12-062003-07-03University Of WashingtonBiodegradable, porous structures useful for growing living tissue, and methods of manufacture
US20030175272A1 (en)2002-03-072003-09-18Medcell Biologics, Inc.Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (en)2002-07-042004-01-22Tegenero Ag Microparticles with CD28-specific monoclonal antibodies
CN1399054A (en)*2002-09-032003-02-26宋有财Rotary car parking plant
US7402431B2 (en)2004-03-012008-07-22Immunovative Therapies, Ltd.T-cell therapy formulation
US7435592B2 (en)*2003-05-132008-10-14Immunovative Therapies, Ltd.Compositions for allogeneic cell therapy
US20110142887A1 (en)2009-12-152011-06-16Immunovative Therapies Ltd.Methods and compositions for liquidation of tumors
US7371228B2 (en)2003-09-192008-05-13Medtronic Vascular, Inc.Delivery of therapeutics to treat aneurysms
PT2573166T (en)2004-02-262016-07-07Immunovative Therapies LtdMethods for preparing t-cells for cell therapy
US7592431B2 (en)2004-02-262009-09-22Immunovative Therapies, Ltd.Biodegradable T-cell Activation device
US7446099B2 (en)2004-02-272008-11-04Nitto Denko CorporationCompositions and methods for biodegradable polymer-peptide mediated transfection
PT1749090T (en)*2004-03-012017-08-28Immunovative Therapies Ltd FORMULATION, METHOD AND COMPOSITION FOR CELL THERAPY
EP1744794A2 (en)2004-03-052007-01-24The Trustees Of Columbia University In The City Of New YorkPolymer-ceramic-hydrogel composite scaffold for osteochondral repair
US8865224B2 (en)*2004-10-142014-10-21Immunovative Therapies Ltd.Allogeneic cellular immunotherapy for opportunistic infection
DK2003978T3 (en)*2006-04-132014-07-07Immunovative Therapies Ltd ALLOGEN CELL THERAPY TO TREAT OPPORTUNIST INFECTION
US20080112963A1 (en)2006-11-132008-05-15Immunovative Therapies, Ltd.Ablative immunotherapy
US7972594B2 (en)*2006-11-132011-07-05Immunovative Therapies Ltd.Ablative immunotherapy
EP2025746A1 (en)*2007-08-162009-02-18Cell Med Research GMBHDendritic cells
US20120128656A1 (en)*2008-05-022012-05-24Immunovative Therapies, Ltd.Vaccine compositions and methods
SG10201901391RA (en)2011-05-032019-03-28Immunovative Therapies LtdInduction of il-12 using immunotherapy

Also Published As

Publication numberPublication date
BR112013028285A2 (en)2017-01-10
US11883490B2 (en)2024-01-30
WO2012151279A2 (en)2012-11-08
WO2012151279A3 (en)2012-12-20
IL229177B (en)2020-07-30
CN103687602A (en)2014-03-26
KR102121492B1 (en)2020-06-11
EP2704732A2 (en)2014-03-12
AU2017204058A1 (en)2017-07-13
JP2014513126A (en)2014-05-29
JP6393186B2 (en)2018-09-19
US11045541B2 (en)2021-06-29
US9233156B2 (en)2016-01-12
EP2704732A4 (en)2015-02-25
JP6615148B2 (en)2019-12-04
CA2838046C (en)2023-03-07
US20240148865A1 (en)2024-05-09
JP2017141287A (en)2017-08-17
US20210268106A1 (en)2021-09-02
US20130101551A1 (en)2013-04-25
CN109876138A (en)2019-06-14
EP2704732B1 (en)2020-03-04
IL229177A0 (en)2013-12-31
KR20140041517A (en)2014-04-04
AU2012250807A1 (en)2013-12-12
PH12013502252A1 (en)2014-01-06
SG194753A1 (en)2013-12-30
US20160089433A1 (en)2016-03-31
PH12013502252B1 (en)2018-09-21
AU2019204699A1 (en)2019-07-18
CA2838046A1 (en)2012-11-08

Similar Documents

PublicationPublication DateTitle
PH12015500940A1 (en)Bruton`s tyrosine kinase inhibitors
AU2018253544A1 (en)Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12014501815A1 (en)Purinone compounds as kinase inhibitors
PH12015501067A1 (en)Pyrrolopyrimidine compounds as kinase inhibitors
MX2014009757A (en)Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
BR112015014462A2 (en) pharmaceutical vectorization of a mammalian cyclic dinucleotide signaling pathway
EP3750549A3 (en)Composition for inducing proliferation or accumulation of regulatory t cells
MX2012007806A (en)Pharmaceutical compositions for oral administration of insulin peptides.
NZ709392A (en)Synergistic bacterial compositions and methods of production and use thereof
SG178991A1 (en)Anti-gitr antibodies
EP2576578A4 (en)Polymorphs of 2'-o-fucosyllactose and producing thereof
GB201106743D0 (en)Novel compounds
PH12014501121A1 (en)Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
SG10201901391RA (en)Induction of il-12 using immunotherapy
IN2014MN00333A (en)
EP3792280A3 (en)Anti-blys antibody
WO2014205199A3 (en)Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2013004061A (en)Cyclosporin analogs.
PH12013500007A1 (en)Piperidine derivatives and their use for the treatment of metabolic disorders
MX2020014208A (en)Optimised subcutaneous therapeutic agents.
GB201213267D0 (en)Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MX2013004062A (en)Cyclosporin analogs.
MX364946B (en)Improved adjuvant system for oral vaccine adminstration.
EP4321218A3 (en)Cancer stem cell targeted cancer vaccines
PH12012502233A1 (en)Methods and compositions for inhibition of treg cells
[8]ページ先頭
©2009-2025 Movatter.jp